{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:41:08Z","timestamp":1768275668822,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>In metastatic colorectal cancer, v\u2010Ki\u2010ras2 Kirsten rat sarcoma viral oncogene homolog (<jats:italic>KRAS<\/jats:italic>) is a predictive biomarker for anti\u2010epidermal growth factor receptor (EGFR) treatment and V\u2010raf murine sarcoma viral oncogene homolog B1 (<jats:italic>BRAF<\/jats:italic>) is a prognostic biomarker. We aimed to determine the impact of <jats:italic>KRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutation as determined from liver metastases specimens on overall survival (OS) in patients following colorectal liver metastasectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Liver metastases specimens (n\u2009=\u2009292) obtained from patients after liver metastasectomy were used to determine the <jats:italic>KRAS\/BRAF<\/jats:italic> genotype. Associations between clinicopathological parameters and <jats:italic>KRAS<\/jats:italic>\/<jats:italic>BRAF<\/jats:italic> genotype were identified by univariate and multivariate analyses using the Cox proportional hazards model. The impact of <jats:italic>KRAS<\/jats:italic>\/<jats:italic>BRAF<\/jats:italic> genotype on survival was analyzed using the Kaplan\u2013Meier method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 5\u2010year survival rate of the cohort was 55.8%. The <jats:italic>KRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutation rates were 38.0 and 2.1%, respectively. <jats:italic>BRAF<\/jats:italic> genotype, but not <jats:italic>KRAS<\/jats:italic>, was found to be an independent prognostic biomarker (HR\u2009=\u20095.181, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) after adjustment for other significant confounding clinicopathological variates: Number of liver metastases (HR\u2009=\u20091.983, <jats:italic>P<\/jats:italic>\u2009=\u20090.009), concomitant extrahepatic disease (HR\u2009=\u20091.858, <jats:italic>P<\/jats:italic>\u2009=\u20090.014), and surgical margin (HR\u2009=\u20093.241, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). <jats:italic>BRAF<\/jats:italic> genotype was an independent prognostic biomarker in patients with liver metastases only after metastasectomy (HR\u2009=\u20096.245, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:italic>BRAF<\/jats:italic> mutation is an independent prognostic biomarker for colorectal liver metastasectomy. J. Surg. Oncol. 2012; 106:123\u2013129. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.23063","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T14:30:30Z","timestamp":1329143430000},"page":"123-129","source":"Crossref","is-referenced-by-count":77,"title":["<i>BRAF<\/i> mutation is a prognostic biomarker for colorectal liver metastasectomy"],"prefix":"10.1002","volume":"106","author":[{"given":"Hao\u2010Wei","family":"Teng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Chung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen\u2010Kou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei\u2010Shone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu\u2010Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng\u2010Kai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chueh\u2010Chuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Fen\u2010Yau","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsei\u2010Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih\u2010Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan\u2010Tzu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huann\u2010Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shung\u2010Haur","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.6155"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605659"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7032"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22448"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.140.2.183"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3452"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0404"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2446"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.9.675"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1489"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.5858\/2008-132-958-CCCIMP","article-title":"Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite\u2010stable colorectal cancers without chromosomal instability","volume":"132","author":"Kakar S","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155473"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.19"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq258"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20854"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08312"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20124"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1165"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1748"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152157"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23388"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4158"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4295"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904160"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.5520"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1586-z"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70330-4"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0031"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/418934a"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.03.014"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi237"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25042"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.26"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq318"},{"key":"e_1_2_7_37_2","unstructured":"BRAF but notKRAS mutation was found to be a poor prognostic biomarker of liver metastasectomy and might be a potential biomarker for resectability of colorectal liver metastases."}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.23063","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.23063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:07:24Z","timestamp":1700582844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.23063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/jso.23063"],"URL":"https:\/\/doi.org\/10.1002\/jso.23063","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]}}}